Patents Assigned to Ardian, Inc.
  • Patent number: 8145316
    Abstract: Methods and apparatus are provided for renal neuromodulation using a pulsed electric field to effectuate electroporation or electrofusion. It is expected that renal neuromodulation (e.g., denervation) may, among other things, reduce expansion of an acute myocardial infarction, reduce or prevent the onset of morphological changes that are affiliated with congestive heart failure, and/or be efficacious in the treatment of end stage renal disease. Embodiments of the present invention are configured for extravascular delivery of pulsed electric fields to achieve such neuromodulation.
    Type: Grant
    Filed: July 25, 2005
    Date of Patent: March 27, 2012
    Assignee: Ardian, Inc.
    Inventors: Mark Deem, Denise Demarais, Douglas Sutton, Hanson Gifford, III, Howard R. Levin, Mark Gelfand, Benjamin J. Clark
  • Patent number: 8131372
    Abstract: A method and apparatus for treatment of heart failure, hypertension and renal failure by stimulating the renal nerve. The goal of therapy is to reduce sympathetic activity of the renal nerve. Therapy is accomplished by at least partially blocking the nerve with drug infusion or electrostimulation. Apparatus can be permanently implanted or catheter based.
    Type: Grant
    Filed: March 19, 2007
    Date of Patent: March 6, 2012
    Assignee: Ardian, Inc.
    Inventors: Howard R. Levin, Mark Gelfand
  • Patent number: 8131371
    Abstract: Methods and apparatus are provided for monopolar neuromodulation, e.g., via a pulsed electric field. Such monopolar neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, monopolar neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such monopolar neuromodulation is performed bilaterally.
    Type: Grant
    Filed: April 13, 2006
    Date of Patent: March 6, 2012
    Assignee: Ardian, Inc.
    Inventors: Denise Demarals, Hanson Gifford, III, Mark Deem, Howard R. Levin, Mark Gelfand, Nicolas Zadno
  • Publication number: 20110264075
    Abstract: Catheter apparatuses, systems, and methods for achieving renal neuromodulation by intravascular access are disclosed herein. One aspect of the present application, for example, is directed to apparatuses, systems, and methods that incorporate a catheter treatment device comprising an elongated shaft. The elongated shaft is sized and configured to deliver an energy delivery element to a renal artery via an intravascular path. Thermal or electrical renal neuromodulation may be achieved via direct and/or via indirect application of thermal and/or electrical energy to heat or cool, or otherwise electrically modulate, neural fibers that contribute to renal function, or of vascular structures that feed or perfuse the neural fibers.
    Type: Application
    Filed: May 28, 2010
    Publication date: October 27, 2011
    Applicant: Ardian, Inc.
    Inventors: Mark S. Leung, Benjamin J. Clark, Kenneth J. Michlitsch, Erik Thai, Andrew Wu, Denise Zarins
  • Publication number: 20110264011
    Abstract: Multi-directional deflectable catheter apparatuses, systems, and methods for achieving renal neuromodulation by intravascular access are disclosed herein. One aspect of the present application, for example, is directed to apparatuses, systems, and methods that incorporate a catheter treatment device comprising an elongated shaft. The elongated shaft is sized and configured to deliver a thermal element to a renal artery via an intravascular path. Thermally or electrical renal neuromodulation may be achieved via direct and/or via indirect application of thermal and/or electrical energy to heat or cool, or otherwise electrically modulate, neural fibers that contribute to renal function, or of vascular structures that feed or perfuse the neural fibers.
    Type: Application
    Filed: August 30, 2010
    Publication date: October 27, 2011
    Applicant: Ardian, Inc.
    Inventors: Andrew Wu, Benjamin J. Clark, Denise Zarins, Erik Thai, Kenneth J. Michlitsch, Mark S. Leung
  • Publication number: 20110257564
    Abstract: Methods and apparatus are provided for treatment of heart arrhythmia via renal neuromodulation. Such neuromodulation may effectuate irreversible electroporation or electrofusion, ablation, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, such neuromodulation is achieved through application of an electric field. In some embodiments, such neuromodulation is achieved through application of neuromodulatory agents, of thermal energy and/or of high intensity focused ultrasound. In some embodiments, such neuromodulation is performed in a bilateral fashion.
    Type: Application
    Filed: March 14, 2011
    Publication date: October 20, 2011
    Applicant: Ardian, Inc.
    Inventors: Denise Demarais, Hanson Gifford, III
  • Publication number: 20110208096
    Abstract: Methods and apparatus are provided for thermally-induced renal neuromodulation. Thermally-induced renal neuromodulation may be achieved via direct and/or via indirect application of thermal energy to heat or cool neural fibers that contribute to renal function, or of vascular structures that feed or perfuse the neural fibers. In some embodiments, parameters of the neural fibers, of non-target tissue, or of the thermal energy delivery element, may be monitored via one or more sensors for controlling the thermally-induced neuromodulation. In some embodiments, protective elements may be provided to reduce a degree of thermal damage induced in the non-target tissues. In some embodiments, thermally-induced renal neuromodulation is achieved via delivery of a pulsed thermal therapy.
    Type: Application
    Filed: March 11, 2011
    Publication date: August 25, 2011
    Applicant: Ardian, Inc.
    Inventors: Denise Demarais, Andrew Wu, Hanson Gifford, III, Mark Deem, Mark Gelfand, Howard R. Levin
  • Publication number: 20110200171
    Abstract: The present disclosure describes methods and apparatus for renal neuromodulation via stereotactic radiotherapy for the treatment of hypertension, heart failure, chronic kidney disease, diabetes, insulin resistance, metabolic disorder or other ailments. Renal neuromodulation may be achieved by locating renal nerves and then utilizing stereotactic radiotherapy to expose the renal nerves to a radiation dose sufficient to reduce neural activity. A neural location element may be provided for locating target renal nerves, and a stereotactic radiotherapy system may be provided for exposing the located renal nerves to a radiation dose sufficient to reduce the neural activity, with reduced or minimized radiation exposure in adjacent tissue. Renal nerves may be located and targeted at the level of the ganglion and/or at postganglionic positions, as well as at pre-ganglionic positions.
    Type: Application
    Filed: January 19, 2011
    Publication date: August 18, 2011
    Applicant: Ardian, Inc.
    Inventors: Robert J. Beetel, Neil C. Barman, Benjamin J. Clark, Paul Friedrichs, Kenneth J. Michlitsch, Karun D. Naga, Andrew Wu, Denise Zarins
  • Publication number: 20110202098
    Abstract: Methods and apparatus are provided for pulsed electric field neuromodulation via an intra-to-extravascular approach, e.g., to effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, changes in cytokine upregulation and other conditions in target neural fibers. In some embodiments, the ITEV PEF system comprises an intravascular catheter having one or more electrodes configured for intra-to-extravascular placement across a wall of patient's vessel into proximity with target neural fibers. With the electrode(s) passing from an intravascular position to an extravascular position prior to delivery of the PEF, a magnitude of applied voltage or energy delivered via the electrode(s) and necessary to achieve desired neuromodulation may be reduced relative to an intravascular PEF system having one or more electrodes positioned solely intravascularly.
    Type: Application
    Filed: January 14, 2011
    Publication date: August 18, 2011
    Applicant: Ardian, Inc.
    Inventors: Denise Demarais, Benjamin J. Clark, Nicolas Zadno, Erik Thai, Hanson Gifford, III
  • Publication number: 20110178570
    Abstract: Methods and apparatus are provided for multi-vessel neuromodulation, e.g., via a pulsed electric field. Such multi-vessel neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, the multi-vessel neuromodulation is applied to neural fibers that contribute to renal function. Such multi-vessel neuromodulation optionally may be performed bilaterally.
    Type: Application
    Filed: December 13, 2010
    Publication date: July 21, 2011
    Applicant: Ardian, Inc.
    Inventor: Denise Demarais
  • Publication number: 20110166499
    Abstract: Methods and apparatus are provided for inducing, monitoring and controlling renal neuromodulation using a pulsed electric field to effectuate electroporation or electrofusion. In some embodiments, tissue impedance, conductance or conductivity may be monitored to determine the effects of pulsed electric field therapy, e.g., to determine an extent of electroporation and its degree of irreversibility. Pulsed electric field electroporation of tissue causes a decrease in tissue impedance and an increase in tissue conductivity. If induced electroporation is reversible, upon cessation of the pulsed electric field, tissue impedance and conductivity should approximate baseline levels; however, if electroporation is irreversible, impedance and conductivity changes should persist. Thus, monitoring of impedance or conductivity may be utilized to determine the onset of electroporation and to determine the type or extent of electroporation.
    Type: Application
    Filed: March 7, 2011
    Publication date: July 7, 2011
    Applicant: Ardian, Inc.
    Inventors: Denise Demarais, Nicolas Zadno
  • Publication number: 20110112400
    Abstract: Catheter apparatuses, systems, and methods for achieving renal neuromodulation by intravascular access are disclosed herein. One aspect of the present application, for example, is directed to apparatuses, systems, and methods that incorporate a catheter treatment device that employs high intensity focused ultrasound. The high intensity focused ultrasound may be used for application of energy to modulate neural fibers that contribute to renal function, or of vascular structures that feed or perfuse the neural fibers. The ultrasound transducer for delivering the energy may be located remotely from the desired treatment area. In particular embodiments, an ultrasound transducer may apply energy at one or more focal zones or focal points that target renal nerves.
    Type: Application
    Filed: November 5, 2010
    Publication date: May 12, 2011
    Applicant: Ardian, Inc.
    Inventors: Charles D. Emery, Mark Gelfand, Howard R. Levin, Denise Zarins
  • Patent number: 7937143
    Abstract: Methods and apparatus are provided for inducing, monitoring and controlling renal neuromodulation using a pulsed electric field to effectuate electroporation or electrofusion. In some embodiments, tissue impedance, conductance or conductivity may be monitored to determine the effects of pulsed electric field therapy, e.g., to determine an extent of electroporation and its degree of irreversibility. Pulsed electric field electroporation of tissue causes a decrease in tissue impedance and an increase in tissue conductivity. If induced electroporation is reversible, upon cessation of the pulsed electric field, tissue impedance and conductivity should approximate baseline levels; however, if electroporation is irreversible, impedance and conductivity changes should persist. Thus, monitoring of impedance or conductivity may be utilized to determine the onset of electroporation and to determine the type or extent of electroporation.
    Type: Grant
    Filed: October 18, 2005
    Date of Patent: May 3, 2011
    Assignee: Ardian, Inc.
    Inventors: Denise Demarais, Nicolas Zadno
  • Publication number: 20110060324
    Abstract: Apparatus, systems, and methods for achieving thermally-induced renal neuromodulation by intravascular access are disclosed herein. One aspect of the present application, for example, is directed to apparatuses, systems, and methods that incorporate a treatment device comprising an elongated shaft. The elongated shaft is sized and configured to deliver a thermal element to a renal artery via an intravascular path. Thermally-induced renal neuromodulation may be achieved via direct and/or via indirect application of thermal energy to heat or cool neural fibers that contribute to renal function, or of vascular structures that feed or perfuse the neural fibers.
    Type: Application
    Filed: October 22, 2010
    Publication date: March 10, 2011
    Applicant: Ardian, Inc.
    Inventors: Andrew Wu, Bejamin J. Clark, Denise Zarins, Erik Thai
  • Patent number: 7873417
    Abstract: Methods and apparatus are provided for pulsed electric field neuromodulation via an intra-to-extravascular approach, e.g., to effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, changes in cytokine upregulation and other conditions in target neural fibers. In some embodiments, the ITEV PEF system comprises an intravascular catheter having one or more electrodes configured for intra-to-extravascular placement across a wall of patient's vessel into proximity with target neural fibers. With the electrode(s) passing from an intravascular position to an extravascular position prior to delivery of the PEF, a magnitude of applied voltage or energy delivered via the electrode(s) and necessary to achieve desired neuromodulation may be reduced relative to an intravascular PEF system having one or more electrodes positioned solely intravascularly.
    Type: Grant
    Filed: November 11, 2009
    Date of Patent: January 18, 2011
    Assignee: Ardian, Inc.
    Inventors: Denise Demarais, Benjamin J. Clark, Nicolas Zadno, Erik Thai, Hanson Gifford, III
  • Patent number: 7853333
    Abstract: Methods and apparatus are provided for multi-vessel neuromodulation, e.g., via a pulsed electric field. Such multi-vessel neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, the multi-vessel neuromodulation is applied to neural fibers that contribute to renal function. Such multi-vessel neuromodulation optionally may be performed bilaterally.
    Type: Grant
    Filed: June 12, 2006
    Date of Patent: December 14, 2010
    Assignee: Ardian, Inc.
    Inventor: Denise Demarais
  • Publication number: 20100268307
    Abstract: Methods and apparatus are provided for intravascularly-induced neuromodulation using a pulsed electric field, e.g., to effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, changes in cytokine upregulation, etc., in target neural fibers. In some embodiments, the intravascular PEF system comprises a catheter having a pair of bipolar electrodes for delivering the PEF, with a first electrode positioned on a first side of an impedance-altering element and a second electrode positioned on an opposing side of the impedance-altering element. A length of the electrodes, as well as a separation distance between the first and second electrodes, may be specified such that, with the impedance-altering element deployed in a manner that locally increases impedance within a patient's vessel, e.g.
    Type: Application
    Filed: June 30, 2010
    Publication date: October 21, 2010
    Applicant: Ardian,Inc.
    Inventors: Denise Demarais, Nicolas Zadno, Benjamin J. Clark, Erik Thai
  • Publication number: 20100249773
    Abstract: The present disclosure comprises handle assemblies for intravascular treatment devices. In one embodiment, a handle assembly comprises an actuator for deflecting a distal region of an intravascular treatment device. In one embodiment, a handle assembly comprises a rotator for rotating an intravascular treatment device independently of the handle assembly. In one embodiment, a handle assembly comprises a rotation limiting element for limiting independent rotation of an intravascular treatment device relative to the handle assembly. Methods and systems for intravascular delivery, deflection and placement of an intravascular treatment device via a handle assembly of the present invention are also provided.
    Type: Application
    Filed: April 13, 2010
    Publication date: September 30, 2010
    Applicant: Ardian, Inc.
    Inventors: Benjamin J. Clark, William R. George, Kenneth J. Michlitsch, John Paul Sam, Erik Thai, Andrew Wu
  • Publication number: 20100222854
    Abstract: Methods and apparatus are provided for thermally-induced renal neuromodulation. Thermally-induced renal neuromodulation may be achieved via direct and/or via indirect application of thermal energy to heat or cool neural fibers that contribute to renal function, or of vascular structures that feed or perfuse the neural fibers. In some embodiments, parameters of the neural fibers, of non-target tissue, or of the thermal energy delivery element, may be monitored via one or more sensors for controlling the thermally-induced neuromodulation. In some embodiments, protective elements may be provided to reduce a degree of thermal damage induced in the non-target tissues.
    Type: Application
    Filed: May 11, 2010
    Publication date: September 2, 2010
    Applicant: Ardian, Inc.
    Inventors: Denise Demarais, Nicolas Zadno, Benjamin J. Clark, Erik Thai, Howard R. Levin, Mark Gelfand
  • Publication number: 20100222851
    Abstract: Methods and apparatus are provided for renal neuromodulation using a pulsed electric field to effectuate electroporation or electrofusion. It is expected that renal neuromodulation (e.g., denervation) may, among other things, reduce expansion of an acute myocardial infarction, reduce or prevent the onset of morphological changes that are affiliated with congestive heart failure, and/or be efficacious in the treatment of end stage renal disease. Embodiments of the present invention are configured for percutaneous intravascular delivery of pulsed electric fields to achieve such neuromodulation.
    Type: Application
    Filed: May 11, 2010
    Publication date: September 2, 2010
    Applicant: Ardian, Inc.
    Inventors: Mark Deem, Hanson Gifford, III, Denise Demarais, Douglas Sutton, Erik Thai, Mark Gelfand, Howard R. Levin